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Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coro-
navirus 2 (SARS-CoV-2) has infected near 5 million people and led to over 0.3 million deaths. Currently,
there is no specific anti-SARS-CoV-2 medication. New drug discovery typically takes more than ten years.
Drug repositioning becomes one of the most feasible approaches for combating COVID-19. This work
curates the largest available experimental dataset for SARS-CoV-2 or SARS-CoV main protease inhibitors.
Based on this dataset, we develop validated machine learning models with relatively low root mean square
error to screen 1553 FDA-approved drugs as well as other 7012 investigational or off-market drugs in Drug-
Bank. We found that many existing drugs might be potentially potent to SARS-CoV-2. The druggability of
many potent SARS-CoV-2 main protease inhibitors is analyzed. This work offers a foundation for further
experimental studies of COVID-19 drug repositioning.
Key words: SARS-CoV-2, COVID-19, Drug repositioning, DrugBank, machine learning, binding affinity
ranking.
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1 Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak in Wuhan, China, in late Decem-
ber 2019 and has rapidly spread around the world. By May 19, 2020, near 5M individuals were infected, and
more than 300K fatalities had been reported. Currently, there is no specific antiviral drug for this epidemic.
It is worth noting that recently, an experimental drug Remdesivir, has been recognized as a promising
anti-SARS-CoV-2 drug. However, the high experimental value of IC50 (11.41 µM) [1] might indicate its
inefficiency in antiviral activities against SARS-CoV-2.
Considering the severity of this widespread dissemination and health threats, panic patients misled by
media flocked to the pharmacies for Chinese medicine herbs, which were reported to “inhibit” SARS-CoV-
2, despite no clinical evidence supporting the claim. Although there is also no evidence for the claimed
Chloroquine’s curing effect, some desperate people take it as “prophylactic” for COVID-19. Many re-
searchers are engaged in developing anti-SARS-CoV-2 drugs [2, 3]. However, new drug discovery is a
long, costly, and rigorous scientific process. A more effective approach is to search for anti-SARS-CoV-2
therapies from existing drug databases.
Drug repositioning (also known as drug repurposing), which concerns the investigation of existing
drugs for new therapeutic target indications, has emerged as a successful strategy for drug discovery due
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to the reduced costs and expedited approval procedures [4–6]. Several successful examples unveil its great
values in practice: Nelfinavir, initially developed to treat the human immunodeficiency virus (HIV), is now
being used for cancer treatments. Amantadine was firstly designed to treat influenza caused by type A
influenza viral infection and is being used for Parkinson’s disease later on [7]. In recent years, the rapid
growth of drug-related datasets, as well as open data initiatives, has led to new developments for com-
putational drug repositioning, particularly structural-based drug repositioning (SBDR). Machine learning,
network analysis, and text mining and semantic inference are three major computational approaches com-
monly applied in drug repositioning [8]. The rapid accumulation of genetic and structural databases [9], the
development of low-dimensional mathematical representations of complex biomolecular structures [10,11],
and the availability of advanced deep learning algorithms have made machine learning-based drug repo-
sition a promising approach [8]. Due to the urgent need for anti-SARS-CoV-2 drugs, a computational drug
repositioning is one of the most feasible strategies for discovering SARS-CoV-2 drugs.
In SBDR, one needs to select one or a few effective targets. Study shows that SARS-CoV-2 genome is
very close to that of the severe acute respiratory syndrome (SARS)-CoV [12]. The sequence identities of
SARS-CoV-2 3CL protease, RNA polymerase, and the spike protein with corresponding SARS-CoV pro-
teins are 96.08%, 96%, and 76%, respectively [13]. We, therefore, hypothesize that a potent SARS 3CL
protease inhibitor is also a potent SARS-CoV-2 3CL protease inhibitor. Unfortunately, there is no effective
SARS therapy at present. Nevertheless, the X-ray crystal structures of both SARS and SARS-CoV-2 3CL
proteases have been reported [14, 15]. Additionally, the binding affinities of SARS-CoV or SARS-CoV-2
3CL protease inhibitors from single-protein experiments are available in various databases or the original
literature. Moreover, the DrugBank contains about 1600 drugs approved by the U.S. Food and Drug Ad-
ministration (FDA) as well as more than 7000 investigational or off-market ones [16]. The aforementioned
information provides a sound basis to develop an SBDR machine learning model for SARS-CoV-2 3CL
protease inhibition.
In responding to the pressing need for anti-SARS-CoV-2 medications, we have carefully collected 314
bonding affinities for SARS-CoV or SARS-CoV-2 3CL protease inhibitors, which is the largest set available
so far for this system. Machine learning models are built for these data points.
Unlike most earlier COVID-19 drug repositioning works, including ours [17], that did not provide a
target-specific cross-validation test, we have carefully optimized our machine learning model with a 10-fold
cross-validation test on SARS-CoV-2 3CL protease inhibitors. We achieve a Pearson correlation coefficient
of 0.78 and a root mean square error (RMSE) of 0.80 kcal/mol, which is much better than that of similar
machine learning models for standard training sets in the PDBbind database (around 1.9 kcal/mol) [18,
19]. We systematically evaluate the binding affinities (BAs) of 1553 FDA-approved drugs as well as 7012
investigational or off-market ones in the DrugBank by our 2D-fingerprint based machine learning model.
Besides, a three-dimensional (3D) pose predictor named MathPose [20] is also applied to predict the 3D
binding poses. With these models, we report the top 30 potential anti-SARS-CoV-2 3CL inhibitors from
the FDA-approved drugs and another top 30 from investigational or off-market ones. We also discuss the
druggability of some potent inhibitors in our training set. The information provides timely guidance for
the further development of anti-SARS-CoV-2 drugs.
2 Results
2.1 Binding affinity prediction and ranking of 1553 FDA-approved drugs
With the SARS-CoV-2 3CL protease as the target, we predict the binding affinities of 1553 FDA-approved
drugs using our machine learning predictor. Based on these predicted affinities, the top 30 potential SARS-
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Table 1: A summary of the top 30 potential anti-SARS-CoV-2 drugs from 1553 FDA-approved drugs with their predicted binding
affinities (unit: kcal/mol), IC50 (µM), and corresponding brand names.
DrugID Name Brand name Predicted IC50
binding affinity
DB01123 Proflavine Bayer Pessaries, Molca, Septicide -8.37 0.72
DB01243 Chloroxine Capitrol -8.24 0.89
DB08998 Demexiptiline Deparon, Tinoran -8.14 1.06
DB00544 Fluorouracil Adrucil -8.11 1.11
DB03209 Oteracil Teysuno -8.09 1.16
DB13222 Tilbroquinol Intetrix -8.08 1.18
DB01136 Carvedilol Coreg -8.06 1.22
DB01033 Mercaptopurine Purinethol -8.04 1.26
DB08903 Bedaquiline Sirturo -8.02 1.29
DB00257 Clotrimazole Canesten -8.00 1.35
DB00878 Chlorhexidine Betasept, Biopatch -8.00 1.35
DB00666 Nafarelin Synarel -8.00 1.35
DB01213 Fomepizole Antizol -7.98 1.39
DB01656 Roflumilast Daxas, Daliresp -7.97 1.41
DB00676 Benzyl benzoate Ascabin, Ascabiol, Ascarbin, Tenutex -7.96 1.45
DB06663 Pasireotide Signifor -7.95 1.47
DB08983 Etofibrate Lipo Merz Retard, Liposec -7.94 1.48
DB06791 Lanreotide Somatuline -7.94 1.48
DB00027 Gramicidin D Neosporin Ophthalmic -7.94 1.48
DB00730 Thiabendazole Mintezol, Tresaderm, and Arbotect -7.93 1.51
DB00643 Mebendazole Vermox, Emverm -7.90 1.59
DB01275 Hydralazine Apresoline -7.90 1.60
DB04920 Clevidipine Cleviprex -7.89 1.61
DB01184 Domperidone Motilium -7.89 1.61
DB00150 Tryptophan Tryptan, Aminomine -7.89 1.63
DB00724 Imiquimod Aldara, Zyclara -7.88 1.63
DB01065 Melatonin Bio-Melatonin, SGard -7.87 1.68
DB00239 Oxiconazole Oxistat -7.86 1.69
DB11071 Phenyl salicylate Urimax -7.86 1.69
DB08909 Glycerol phenylbutyrate Ravicti -7.85 1.73
CoV-2 inhibitors from the FDA-approved drugs are shown in Table 1. A complete list of the predicted
values for 1553 FDA-approved drugs is given in the Supporting Material.
We briefly describe the top 10 predicted potential anti-SARS-CoV-2 drugs from the FDA-approved set.
The most potent one is Proflavine, an acriflavine derivative. It is a disinfectant bacteriostatic against many
gram-positive bacteria. Proflavine is toxic and carcinogenic in mammals and so it is used only as a surface
disinfectant or for treating superficial wounds. Under the circumstance of the SARS-CoV-2, this drug might
be used to clean skin or SARS-CoV-2 contaminated materials, offering an extra layer of protection. The sec-
ond drug is Chloroxine, also an antibacterial drug, which is used in infectious diarrhea, disorders of the in-
testinal microflora, giardiasis, inflammatory bowel disease. It is notable that this drug belongs to the same
family with Chloroquine, which was once considered for anti-SARS-CoV-2. However, according to our
prediction, Chloroquine is not effective for SARS-CoV-2 3CL protease inhibition (BA: -6.92 kcal/mol). The
third one, Demexiptiline, a tricyclic antidepressant, acts primarily as a norepinephrine reuptake inhibitor.
The next one, Fluorouracil, is a medication used to treat cancer. By injection into a vein, it is used for colon
cancer, esophageal cancer, stomach cancer, pancreatic cancer, breast cancer, and cervical cancer. The fifth
4
drug, Oteracil, is an adjunct to antineoplastic therapy, used to reduce the toxic side effects associated with
chemotherapy. The next one, Tilbroquinol, is a medication used in the treatment of intestinal amoebiasis.
The seventh drug, Carvedilol, is a medication used to treat high blood pressure, congestive heart failure,
and left ventricular dysfunction. The number eight drug, Mercaptopurine, is a medication used for cancer
and autoimmune diseases. Specifically, it treats acute lymphocytic leukemia, chronic myeloid leukemia,
Crohn’s disease, and ulcerative colitis. The next one is Bedaquiline, which is a medication used to treat
active tuberculosis, specifically multi-drug-resistant tuberculosis along with other tuberculosis. The num-
ber ten drug, Clotrimazole, is an antifungal medication, which is used to treat vaginal yeast infections, oral
thrush, diaper rash, pityriasis versicolor, and types of ringworm including athlete’s foot and jock itch.
2.2 Binding affinity prediction and ranking of 7012 investigational or off-market drugs
Using our validated machine elarning model, we present the binding affinity prediction and ranking of
7012 investigational or off-market drugs. We list the top 30 from the investigational or off-market drugs in
Table 2. A complete list of the predicted values can be found in the Supporting Material.
Compared FDA-approved drugs, investigational or off-market drugs are more promising SARS-CoV-2
inhibitors. Among them, DEBIO-1347 has a binding affinity of -9.02 kcal/mol (IC50: 0.24 µM). Another
top-ranking drug is 3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE, which has a binding affinity of -9.01
kcal/mol (IC50: 0.24 µM).
2.3 Pose prediction
The prediction of binding poses is also another important task in drug discovery. For example, protein-
ligand pose and binding affinity predictions are major tasks in D3R Grand Challenges [21]. The availability
of binding poses enables researchers to understand the molecular mechanism of protein-drug interactions
further. In this work, utilizing the MathPose [22] developed by us recently, we predict and analyze the
binding poses of our predicted top 3 FDA approved drugs as well as our predicted top 3 investigational or
off-market ones.
3 Discussion
3.1 Analysis of predicted top FDA-approved drugs
3.1.1 Top 3 FDA-approved drugs
The first-ranking candidate from the FDA-approved drugs is Proflavine (see Figure 1(a)), with a predicted
binding affinity to the SARS-CoV-2 main protease of -8.37 kcal/mol. The predicted binding pose using our
MathPose [22] is illustrated in Figure 1(b). It reveals that there are two hydrogen bonds formed between
the drug and the SARS-CoV-2 main protease. The first one is between one amino of Proflavine and the O
atom in the main chain of the residue Glu166 of the protease. The second one is between the other amino
of the drug and the five-member ring in the side chain of the residue His41 of the protease. As a result, the
binding affinity is promising.
The predicted second-best drug is Chloroxine (see Figure 1(c)). Its predicted binding affinity is -8.24
kcal/mol. Between the drug and the protease, there are two hydrogen bonds (see Figure 1(d)): One is
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Table 2: A summary of top 30 potential anti-SARS-CoV-2 drugs from 7012 investigational or off-market drugs with predicted binding
affinities (BAs) (unit: kcal/mol), IC50 (µM), and corresponding trade names.
DrugID Name Predicted IC50
BA
DB12903 DEBIO-1347 -9.02 0.24
DB07959 3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE -9.01 0.24
DB07301 9H-CARBAZOLE -8.96 0.27
DB07620 2-[(2,4-DICHLORO-5-METHYLPHENYL)SULFONYL] -8.89 0.30
-1,3-DINITRO-5-(TRIFLUOROMETHYL)BENZENE
DB08036 6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-5-one -8.89 0.30
DB08440 N-1,10-phenanthrolin-5-ylacetamide -8.83 0.33
DB01767 Hemi-Babim -8.80 0.35
DB06828 5-[2-(1H-pyrrol-1-yl)ethoxy]-1H-indole -8.73 0.39
DB14914 Flortaucipir F-18 -8.69 0.42
DB15033 Flortaucipir -8.69 0.42
DB13534 Gedocarnil -8.67 0.44
DB02365 1,10-Phenanthroline -8.64 0.45
DB09473 Indium In-111 oxyquinoline -8.64 0.45
DB08512 6-amino-2-[(1-naphthylmethyl)amino]-3,7 -8.60 0.48
-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
DB01876 Bis(5-Amidino-2-Benzimidazolyl)Methanone -8.60 0.49
DB07919 7-METHOXY-1-METHYL-9H-BETA-CARBOLINE -8.59 0.49
DB02089 CP-526423 -8.59 0.50
DB07837 [4-(5-naphthalen-2-yl-1H-pyrrolo[2,3-b] -8.53 0.55
pyridin-3-yl)phenyl]acetic acid
DB08073 (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL) -8.53 0.55
PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
DB08267 6-amino-4-(2-phenylethyl)-1,7-dihydro-8H-imidazo[4,5-g] -8.52 0.56
quinazolin-8-one
DB02390 5-Bromo-N[2-(Dimethylamino)Ethyl]-9-Aminoacridine-4 -8.50 0.57
-Carboxamide
DB07588 3,4-DI-1H-INDOL-3-YL-1H-PYRROLE-2,5-DICARBOXYLIC ACID -8.50 0.58
DB03213 Bis(5-Amidino-2-Benzimidazolyl)Methane Ketone -8.47 0.61
DB08656 5-amino-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide -8.47 0.61
DB01976 Aminoanthracene -8.43 0.65
DB04716 2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZ[H] -8.43 0.65
-IMIDAZ
[4,5-F]ISOQUINOLIN-7-ONE
DB08066 N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE -8.42 0.66
DB07457 3-[1-(3-AMINOPROPYL)-1H-INDOL-3-YL]-4-(1H-INDOL-3-YL)-1H -8.41 0.67
-PYRROLE-2,5-DIONE
DB01765 (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid -8.40 0.68
DB08065 2-(1H-pyrazol-3-yl)-1H-benzimidazole -8.40 0.68
formed by the H atom of the hydroxy of the drug with the main-chain O atom of the residue Leu141. The
other one is between the hydroxy O atom of the drug and the amino in the main chain of Cys145.
The third one, Demexiptiline (see Figure 1(e)), has a predicted binding affinity of -8.14 kcal/mol. The
hydrogen bond between this drug and the protease are formed by the H atom of the amino on the tail of the
drug with the side-chain O atom of Ser144. Hydrophobic interactions also play a critical role in the binding.
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3.1.2 The binding affinities of the protease-based drugs
Table 3: A summary of the predicted binding affinities (BAs) (unit: kcal/mol) and IC50 (µM) of the existing protease inhibitors.
Numbers in parenthesis are predictions from the literature [23].
DrugID Predicted IC50 DrugID Predicted IC50
Binding Affinity BA
Remikiren -7.42 3.57 Moexipril -6.55 15.63
Candoxatril -7.22 5.05 Trandolapril -6.54 17.70
Darunavir -7.16 5.55 Lopinavir -6.50 16.92
Isoflurophate -7.09 6.28 Spirapril -6.49 17.16
Atazanavir -7.03 (-9.57) 6.96 Dabigatran etexilate -6.46 17.96
Argatroban -7.02 6.98 Apixaban -6.44 18.84
Sitagliptin -6.93 8.22 Tipranavir -6.39 20.36
Fosamprenavir -6.92 8.26 Lisinopril -6.35 21.87
Quinapril -6.91 8.45 Perindopril -6.34 22.10
Amprenavir -6.82 9.83 Cilazapril -6.31 23.36
Benazepril -6.81 10.05 Ritonavir -6.26 (-8.47) 25.50
Rivaroxaban -6.74 11.21 Ximelagatran -6.24 26.14
Fosinopril -6.74 11.28 Vildagliptin -6.15 30.38
Telaprevir -6.73 11.54 Cilastatin -6.15 30.40
Captopril -6.72 11.68 Indinavir -6.11 32.91
Ramipril -6.66 12.84 Saxagliptin -6.07 35.27
Enalapril -6.66 12.93 Nelfinavir -6.05 36.23
Alogliptin -6.62 13.90 Boceprevir -6.00 39.16
Linagliptin -6.58 14.73 Simeprevir -5.77 (-8.29) 58.25
Saquinavir -6.56 15.26 Ecabet -5.71 64.15
It is interesting to analyze the binding affinities of the existing drugs developed as protease inhibitors.
Table 3 shows their predicted binding affinities. The predicted values by a recent study [23] are given in the
parenthesis, it appears that these values are overestimated. Notably, the current protease inhibitors do not
have a substantial effect on the SARS-CoV-2 protease. A possible reason is that SARS-CoV-2 3CL protease
is genetically and structurally different from most other known proteases.
3.1.3 Comparison to experimental data
In this section, we are interested in comparing our predicted binding affinities to the corresponding experi-
mental ones of some existing drugs outside our training set. Table 4 lists our predictions along with the ex-
perimental values of these drugs. These experimental data are extracted from the recent literature [1,24,25].
The RMSE of experimental values and predicted ones is 0.87 kcal/mol, showing a good agreement. It is
to point out that all these data were obtained from cell-culture experiments, leading to discrepancies when
comparing these experimental values to our results only tailoring to the inhibition of the SARS-CoV-2 3CL
protease. For example, the target of Remdesivir is the RNA-dependent RNA polymerase rather than the
3CL protease.
3.2 Analysis of top 3 investigational or off-market drugs
Among the investigational or off-market drugs, the top-ranking candidate is DEBIO-1347 (see Figure 2(a)).
Its binding affinity with the SARS-CoV-2 protease is predicted to be -9.02 kcal/mol. The MathPose pre-
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Table 4: A summary of our predicted binding affinities (BAs) and the corresponding experimental ones of some existing drugs against
SARS-CoV-2. All numbers are in kcal/mol unit.
DrugID Experiment Prediction DrugID Experiment Prediction
Remdesivir -6.74 [1] -6.29 Perhexiline -7.08 [1] -6.67
Chloroquine -7.00 [1] -6.92 Loperamide -6.86 [1] -6.98
Lopinavir -6.87 [1] -6.51 Mefloquine -7.31 [1] -6.89
Niclosamide -8.93 [1] -7.66 Amodiaquine -7.21 [1] -6.93
Proscillaridin -7.75 [1] -6.50 Phenazopyridine -6.21 [1] -7.51
Penfluridol -7.23 [1] -6.54 Clomiphene -7.19 [1] -7.12
Toremifene -7.42 [1] -7.20 Digoxin -9.16 [1] -7.00
Hexachlorophene -8.24 [1] -7.37 Thioridazine -7.05 [1] -6.96
Salinomycin -9.02 [1] -7.00 Pyronaridine -6.13 [1] -6.68
Ciclesonide -7.31 [1] -7.04 Ceritinib -7.56 [1] -6.77
Osimertinib -7.48 [1] -6.62 Lusutrombopag -7.39 [1] -6.78
Gilteritinib -7.05 [1] -5.57 Berbamine -6.96 [1] -6.87
Ivacaftor -7.07 [1] -6.74 Mequitazine -7.00 [1] -6.41
Dronedarone -7.37 [1] -6.19 Eltrombopag -6.93 [1] -6.17
Fluphenazine -7.08 [24] -6.29 Benztropine -6.63 [24] -6.94
Chlorpromazine -7.50 [24] -7.00 Terconazole -6.71 [24] -7.18
Simeprevir -6.67 [25] -5.77 Boceprevir -7.34 [25] -6.00
Narlaprevir -7.14 [25] -6.38
dicted pose is illustrated in Figure 2(b). It indicates a hydrogen bond network formed between the drug and
the protease leads to the moderately high binding affinity. This network consists of two hydrogen bonds:
the first hydrogen bond is between one N atom in the Pyrazole of the drug and the main-chain amino of
the residue Glu166 of the protease; the second one is between one N atom in the 1H-1,3-benzodiazole of the
drug and the main-chain amino of the residue Gly143 of the protease.
The second-best investigational drug is 3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE (Figure 2(c)) with
a predicted binding affinity of -9.01 kcal/mol. Figure 2(d) reveals that the drug forms two hydrogen bonds
with the protease. One is between one N atom in the 1H-1,3-benzodiazole of the drug and the main-chain
O atom of the residue Glu166 of the protease. The other is between one N atom in the 1H-indazole of the
drug and the main-chain O atom of the residue His164 of the protease.
The third one, 9H-CARBAZOLE (see Figure 2(e)), also has a promising predicted affinity of -8.96 kcal/mol.
One can see from Figure 2(f), a strong hydrogen bond is formed between the N atom of the drug and the
main-chain O atom of the residue His164 of the protease. The hydrophobic interactions play an essential
role in the binding as well.
3.3 Analysis of top SARS-CoV/SARS-CoV-2 3CL-protease inhibitors
Note that, in our training set collected from the existing experimental data, 21 samples have binding affin-
ity values lower than -9 kcal/mol. Table 5 provides a list top 30 SARS-CoV/SARS-CoV-2 3CL-protease
inhibitors with their experimental binding affinities and estimated druggable properties. Moreover, 4 of
these 21 samples have 3D experimental structures available. Although these inhibitors are not on the mar-
ket yet, they serve as good starting points for the design of anti-SARS-CoV-2 drugs. A full list of our training
compounds is given in the Supporting Material.
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3.3.1 Binding interaction analysis of the top 3 experimental structures
Among the SARS-CoV/SARS-CoV-2 3CL-protease complexes with their 3D experimental structures avail-
able, the one with the PDB ID 2zu4 [26] is the most potent one with a binding affinity over -10 kcal/mol.
This high binding affinity is due to a strong hydrogen bond network between the inhibitor and the protease,
which consists of as many as 7 hydrogen bonds. These 7 hydrogen bonds are formed by the inhibitor with
protease residues Gln189, Gly143, His163, His164, and Glu166 of the protease.
The second-best 3D-experimental structure is the one with the PDB ID 3avz [27] and its binding affinity
is -9.80 kcal/mol. A hydrogen bond network, including 7 bonds, plays an essential role in this strong
binding. This network is between the inhibitor and protease residues Gln192, Thr190, His164, His163,
Glu166, and Gly143.
The PDB ID of the third one is 2zu5 [26] with a binding affinity of -9.56 kcal/mol. A strong hydrogen
bond network with 7 bonds can also be found in the structure. The protease residues in the network are
Glu166, Phe148, His163, His164, Gly143, and Gln189.
Since His163, His164, and Glu166 emerge in the hydrogen bond networks of all these three structures,
it suggests that these three residues are critical to inhibitor binding.
3.3.2 The analysis of log P, log S, and synthesizability of 3 top SARS-CoV/SARS-CoV-2 3CL-protease
inhibitors inhibitors
The partition coefficient (log P), aqueous solubility (log S), and synthesizability are also critical medical
chemical properties for deciding whether a compound can be a drug or not. Notably, synthesizability is
always in terms of synthetic accessibility score (SAS), for which 1 means the easiest, 10 means the hardest.
Here, we first calculate the log Ps, log Ss, and SASs of the 1553 FDA-approved drugs (See the Supporting
Material), then investigate whether the three properties of the inhibitors in the top 3 experimental structures
are in the preferred ranges of that of the FDA-approved drugs.
According to the log P distribution of the FDA-approved drugs in the Supporting Material, the log P
interval with a large population of the FDA-approved drugs is between -0.14 and 4.96. The log P values of
the top 3 inhibitors are 2.35, -1.35, and -0.46, respectively.
The log S distribution reveals that the preferred range of log S is between -5.12 and 1.76. The log S values
of the top 3 inhibitors are -3.53, -2.33, and -4.39.
In the SAS distribution, most of the FDA-approved drugs have SASs between 1.84 and 3.94. The SAS
values of the top 3 inhibitors are 4.04, 4.65, and 4.27.
So in summary, for the inhibitor in the first ranking PDB structure 2zu4, its log P and log S are quite good
for a drug. The SAS is a little higher, but it is still not so hard to synthesize: 344 of the 1553 FDA-approved
drug have larger SASs than this inhibitor, even 56 of them have SASs over 6.
Similarly, for the 3avz and 2zu5 inhibitors, their log Ss are very promising. The log Ps and SASs are some
out of the preferred ranges, but still, many FDA-approved drugs have worse log Ps and SASs than theirs.
As a result, these top 3 inhibitors, especially the first one, could be good starting points for developing
anti-SARS-CoV2 drugs. Obviously, their toxicity will be a major concern for any further development.
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Table 5: A summary of top 30 SARS-CoV-2 main protease inhibitors in the training set with experimental binding affinities (unit:
kcal/mol), IC50 (µM), as well as calculated synthesizability, log P and log S.
ID Binding Affinity IC50 synthesizability log P log S
CHEMBL497141 -11.08 0.01 2.4 2.18 -3.65
PDB ID 2zu4 -10.12 0.04 4.04 2.35 -3.53
CHEMBL222234 -9.95 0.05 2.26 2.66 -3.59
CHEMBL2442057 -9.94 0.05 2.26 5.39 -6.22
CHEMBL213054 -9.92 0.05 4.2 3.15 -3.81
CHEMBL212080 -9.87 0.06 4.25 3.15 -3.76
CHEMBL222840 -9.85 0.06 2.23 2.55 -3.37
CHEMBL398437 -9.85 0.06 2.29 4.12 -5.39
CHEMBL222769 -9.82 0.06 2.16 4.87 -5.73
PDB ID 3avz -9.80 0.07 4.65 -1.35 -2.33
CHEMBL225515 -9.80 0.07 2.22 3.44 -4.28
CHEMBL1929019 -9.80 0.07 4.23 -0.77 -2.41
CHEMBL222893 -9.57 0.10 2.21 4.17 -5.01
PDB ID 2zu5 -9.56 0.10 4.27 3.79 -4.39
PDB ID 3atw -9.55 0.10 4.63 -0.46 -2.47
CHEMBL334399 -9.50 0.11 2.20 3.06 -4.17
CHEMBL253905 -9.43 0.12 2.43 4.78 -5.45
CHEMBL403932 -9.42 0.12 1.94 4.11 -4.97
CHEMBL254103 -9.25 0.16 2.10 2.35 -3.34
CHEMBL426898 -9.23 0.17 2.17 3.70 -4.72
CHEMBL402379 -9.11 0.21 2.34 4.12 -5.36
CHEMBL222628 -8.96 0.27 2.66 2.41 -3.52
CHEMBL1929020 -8.96 0.27 3.97 0.76 -2.58
CHEMBL212218 -8.89 0.30 2.71 4.97 -5.16
PDB ID 2gz7 -8.89 0.30 2.71 4.97 -5.16
PMC2597651 1 -8.88 0.31 2.45 4.49 -5.15
CHEMBL2402686 -8.84 0.33 3.69 3.14 -4.15
CHEMBL252662 -8.83 0.33 2.11 2.86 -4.06
CHEMBL222735 -8.82 0.34 1.91 2.96 -3.84
CHEMBL1929022 -8.82 0.34 4.01 -0.27 -2.42
4 Material and methods
4.1 Sequence identity and 3D structure similarity analysis
The sequence identity is defined as the percentage of characters that match exactly between two differ-
ent sequences. Calculated by SWISS-MODEL [28], the sequence identities between the SARS-CoV-2 3CL
protease and that of SARS-CoV, MERS-CoV, HKU-1, OC43, HCoVNL63, 229E, and HIV are 96.1%, 52.0%,
49.0%, 48.4%, 45.2%, 41.9%, and 23.7%, respectively.
It is seen that the SARS-CoV-2 3CL protease is very close to the SARS-CoV 3CL protease, but distin-
guished from other proteases. SARS-CoV-2 has a strong genetic relationship with SARS-CoV, the sequence
alignment in Figure 4 further confirms their relationship.
Not only are the sequences highly identical, but also, as shown in Fig. 5 the 3D crystal structures of the
SARS-CoV-2 3CL protease is also substantially similar to that of SARS-CoV 3CL protease. Particularly, the
RMSD of two structures at the binding site is only 0.42 A˚.
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The high sequence and structure similarity between the two proteases suggests that anti-SARS-CoV
chemicals can be equally effective for the treatment of SARS-CoV-2. It means the available experimental
data of SARS-CoV protease inhibitors can also be used as the training set to discover new inhibitors of
SARS-CoV-2 protease. Our SARS-CoV-2 BA training set contains 314 compounds with their binding affini-
ties to the SARS-CoV or SARS-CoV-2 3CL protease from single-protein experiments available.
4.2 The training set of SARS-CoV-2 3CL protease inhibitors
We collect the training set from single-protein experimental data of SARS/SARS-CoV-2 3CL protease in
public databases or the related literature.
ChEMBL is a manually curated database of bioactive molecules [29]. Currently, ChEMBL contains more
than 2 million compounds only in the SMILES string format. In ChEMBL, we find 277 SARS-CoV or SARS-
CoV-2 3CL protease inhibitors with reported Kd/IC50 from single-protein experiments.
Another database is PDBbind. The PDBbind database includes all the protein-ligand complexes with
the crystal structures deposited in the Protein Data Bank (PDB) and their binding affinities in the form of
Kd, Ki or IC50 reported in literature [30]. The newest PDBbind v2019 consists of 17,679 complexes as well
as the binding affinities. We find another 30 inhibitors in the PDBbind v2019.
Additionally, binding affinities for four other SARS-CoV main protease inhibitors and three other SARS-
CoV-2 main protease inhibitors are extracted from Ref. [31] and Ref. [15], respectively. Therefore, we col-
lected 314 SARS-CoV/SARS-CoV-2 3CL protease inhibitors with available experimental binding affinities.
The binding affinity range in this set is from -3.68 kcal/mol to -11.08 kcal/mol. The distribution is
depicted in Figure 6. The top 30 inhibitors in the training set are summarized in Table 5.
4.3 The FDA-approved drugs and investigational or off-market ones
DrugBank (www.drugbank.ca) [16] is a richly annotated, freely accessible online database that integrates
massive drug, drug target, drug action, and drug interaction information about FDA-approved drugs as
well as investigational or off-market ones. Due to the high quality and sufficient information contained
in, the DrugBank has become one of the most popular reference drug resources used all over the world.
In current work, we extract 1553 FDA-approved drugs and 7012 investigational or off-market ones from
DrugBank, and evaluate their binding affinities to the SARS-CoV-2 3CL protease.
4.4 The log P, log S and synthesizability calculations
In this work, the log P and synthesizability values are calculated by RDKit [32]; the synthesizability in RDkit
is in terms of synthetic accessibility score, 1 means the easiest, 10 means the hardest. The log S values are
obtained via Alog PS 2.1 [33].
4.5 MathPose
The 3D binding poses in this work are predicted by the MathPose, a 3D pose predictor which converts
SMILES strings into 3D poses with references of target molecules. It was the top performer in D3R Grand
Challenge 4 in predicting the poses of 24 beta-secretase 1 (BACE) binders [22]. For one SMILES string,
around 1000 3D structures can be generated by a common docking software tool, i.e., GLIDE [34]. Moreover,
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a selected set of known complexes is re-docked by the three docking software packages mentioned above
to generate at 100 decoy complexes per input ligand as a machine learning training set. The machine
learning labels will be the calculated root mean squared deviations (RMSDs) between the decoy and native
structures for this training set. Furthermore, MathDL models [22] are set up and applied to select the top-
ranked pose for the given ligand.
4.6 The machine learning-based binding affinity predictor
In the current work, we develop a machine learning model for predicting the binding affinities of SARS-
CoV-2 inhibitors. Since the size of the training set in our current case study is only 314, we apply the
gradient boosting decision tree (GBDT) [35] model because of its accuracy for handling small datasets.
This GBDT predictor is constructed using the gradient boosting regressor module in scikit-learn (version
0.20.1) [36].
The 2D fingerprints of compounds are used as the input features to our GBDT predictor. Our previous
study [37] shows that, the consensus of ECFP4 [38], Estate1 [39] and Estate2 [39] fingerprints performs the
best on binding-affinity prediction tasks. In this work, we also make use of this consensus. The 2D finger-
prints are calculated from SMILES strings using RDKit software (version 2018.09.3) [32]. The GBDT parame-
ters in our predictor are, for ECFP4, n estimators=10000,max depth=7,min samples split=3,learnin rate=0.01,
subsample=0.3,max features=’sqrt’; for Estate1 and Estate2, n estimators=2000,max depth=9,min samples split=3,
learnin rate=0.01,subsample=0.3,max features=’sqrt’.
4.7 The 10-fold cross-validation of the binding affinity predictor
Table 6: The 10-fold cross-validation test of the machine learning model on the SARS-CoV-2 BA training set.
Rp τ RMSE (kcal/mol) Rp τ RMSE (kcal/mol)
Fold 1 (Train) 0.998 0.976 0.089 Fold 6 (Train) 0.997 0.972 0.097
Fold 1 (Test) 0.777 0.565 0.762 Fold 6 (Test) 0.746 0.541 0.774
Fold 2 (Train) 0.997 0.970 0.102 Fold 7 (Train) 0.997 9.971 0.098
Fold 2 (Test) 0.807 0.654 0.804 Fold 7 (Test) 0.812 0.636 0.822
Fold 3 (Train) 0.997 0.971 0.096 Fold 8 (Train) 0.997 0.968 0.099
Fold 3 (Test) 0.822 0.632 0.743 Fold 8 (Test) 0.758 0.550 0.776
Fold 4 (Train) 0.997 0.969 0.101 Fold 9 (Train) 0.997 0.971 0.098
Fold 4 (Test) 0.801 0.595 0.756 Fold 9 (Test) 0.709 0.536 0.909
Fold 5 (Train) 0.998 0.976 0.081 Fold 10 (Train) 0.997 0.968 0.104
Fold 5 (Test) 0.751 0.541 0.815 Fold 10 (Test) 0.792 0.620 0.799
Average (Train) 0.997 0.971 0.097
Average (Test) 0.777 0.587 0.796
In this section, we validate the performance of our machine learning predictor for the 314 inhibitors in
the SARS-CoV-2 BA training set with the description provided in Table 6.
Table 6 reveals that our machine learning predictor is trained with the averaged train accuracy being
the Pearson correlation coefficient (Rp) = 0.997, the Kendall’s τ (τ ) = 0.971, RMSE = 0.097 kcal/mol. These
metrics are based on the averaged values across 10 folds and these results indicate our model is well trained.
Their averaged test performances across 10-fold of the whole SARS-CoV-2 BA set are found to beRp = 0.777,
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τ = 0.587, RMSE = 0.796 kcal/mol. These results endorse the reliability of our model in the binding affinity
prediction of SARS-CoV-2 inhibitors.
5 Conclusion
The current pneumonia outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), has evolved into a global pandemic. Although currently there is no effective antiviral medicine against
the SARS-CoV-2, the 3CL proteases of SARS-CoV-2 and SARS-CoV have a sequence identity of 96.1% and
the binding-site RMSD of 0.42 A˚, which provides a solid basis for us to hypothesize that all potential anti-
SARS-CoV chemotherapies are also effective anti-SARS-CoV-2 molecules. In this work, we curate 314
SARS-CoV-2/SARS-CoV 3CL protease inhibitors with available experimental binding data from various
sources to form a machine learning training set. Using this training set, we develop a gradient boosted
decision trees (GBDT) model to predict the binding affinities of potential SARS-CoV-2 3CL protease in-
hibitors. The 10-fold cross-validation shows our model has a Pearson correlation coefficient of 0.78 and a
relatively low root mean square error of 0.80 kcal/mol. A total of 8565 drugs from DrugBank is evaluated
by their predicted binding affinities. We highlight 30 FDA-approved drugs as well as 30 investigational or
off-market drugs as potentially potent medications against SARS-CoV-2. We also analyze the druggability
of some potent inhibitors in our training set. This work serves as a foundation for the further experimental
development of anti-SARS-CoV-2 drugs.
Supporting Material
The tables of experimental binding affinities for 314 SARS-CoV-2 3CL protease inhibitors, the predicted
binding affinities of 1553 FDA-approved drugs and 7012 investigational or off-market drugs are available
in Supporting-Material.xlsx. Also, a brief introduction of the MathDL developed by us is in supplementary
figures.
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(a) Proflavine, -8.37 kcal/mol
(b) SARS-CoV-2 protease and Proflavine complex
(c) Chloroxine, -8.24 kcal/mol
(d) SARS-CoV-2 protease and Chloroxine complex
(e) Demexiptiline, -8.14 kcal/mol
(f) SARS-CoV-2 protease and Demexiptiline complex
Figure 1: Proflavine, Chloroxine, Demexiptiline and their complexes with SARS-CoV-2 protease.
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(a) DEBIO-1347, -9.02 kcal/mol
(b) SARS-CoV-2 protease and DEBIO-1347 complex
(c) 3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE,
-9.01 kcal/mol
(d) SARS-CoV-2 protease and 3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE complex
(e) 9H-CARBAZOLE, -8.96 kcal/mol
(f) SARS-CoV-2 protease and 9H-CARBAZOLE complex
Figure 2: DEBIO-1347, 3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE, 9H-CARBAZOLE and their complexes with
SARS-CoV-2 protease.
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(a) 2zu4 inhibitor, -10.12 kcal/mol
(b) 2zu4 complex
(c) 3avz inhibitor, -9.80 kcal/mol
(d) 3avz complex
(e) 2zu5 inhibitor, -9.56 kcal/mol
(f) 2zu5 complex
Figure 3: The inhibitors and complexes from the top 3 PDBbind structures, 2zu4, 3avz, and 2zu5.
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Figure 4: The 3CL protease sequence alignment between SARS-CoV-2, SARS-CoV, MERS, OC43, HCoVNL63, HKU-1, 229E, and HIV.
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Figure 5: Illustration of the 3D structure similarity between the SARS-CoV-2 3CL protease (PDB ID: 6Y2F, in gold) and SARS-CoV 3CL
protease (PDB ID: 2A5I, in green). The anti-SARS inhibitors in dark color indicate the binding site.
Figure 6: The experimental ∆G distribution of the training set of SARS-CoV-2 3CL protease inhibitors.
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